Akari Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 16

Employees

  • Stock Symbol
  • AKTX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $6.80
  • (As of Friday Closing)

Akari Therapeutics General Information

Description

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Contact Information

Website
www.akaritx.com
Formerly Known As
Volution Immuno Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 75/76 Wimpole Street
  • London W1G 9RT
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 75/76 Wimpole Street
  • London W1G 9RT
  • England, United Kingdom
+44 020

Akari Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akari Therapeutics Stock Performance

As of 13-Nov-2026, Akari Therapeutics’s stock price is $6.80. Its current market cap is $15.5M with 2.29M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.80 $6.51 $3.02 - $29.32 $15.5M 2.29M 63.7K

Akari Therapeutics Financials Summary

As of 30-Jun-2026, Akari Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 15,897 12,864 31,050 10,457
Revenue 0 0 0 0
EBITDA (31,838) (17,353) (19,541) (10,086)
Net Income (30,960) (17,298) (19,791) (10,008)
Total Assets 38,624 47,892 50,562 4,355
Total Debt 693 754 3,260 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Akari Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Akari Therapeutics‘s full profile, request access.

Request a free trial

Akari Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Akari Therapeutics‘s full profile, request access.

Request a free trial

Akari Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around no
Drug Discovery
London, United Kingdom
16 As of 2026

Waltham, MA
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akari Therapeutics Competitors (57)

One of Akari Therapeutics’s 57 competitors is Apellis Pharmaceuticals, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
EpimAb Biotherapeutics Venture Capital-Backed Shanghai, China
BeOne Medicines Formerly PE-Backed Beijing, China
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Cogent Biosciences Formerly VC-backed Waltham, MA
You’re viewing 5 of 57 competitors. Get the full list »

Akari Therapeutics Patents

Akari Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2010247814-A1 Lipid-polymer conjugates, their preparation and uses thereof Active 11-May-2009
AU-2010247814-B2 Lipid-polymer conjugates, their preparation and uses thereof Inactive 11-May-2009
EP-2429532-A1 Lipid-polymer conjugates, their preparation and uses thereof Inactive 11-May-2009
EP-2429532-A4 Lipid-polymer conjugates, their preparation and uses thereof Inactive 11-May-2009
AU-2007320737-A1 Contact lens compositions Active 14-Nov-2006 A61K9/0048
To view Akari Therapeutics’s complete patent history, request access »

Akari Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akari Therapeutics Acquisitions (2)

Akari Therapeutics’s most recent deal was a Merger/Acquisition with Peak Bio for . The deal was made on 14-Nov-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Peak Bio 14-Nov-2024 Merger/Acquisition Drug Discovery
Celsus Therapeutics 18-Sep-2015 Merger/Acquisition Drug Discovery
To view Akari Therapeutics’s complete acquisitions history, request access »

Akari Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Peak Bio Palo Alto, CA 2015

Akari Therapeutics FAQs

  • When was Akari Therapeutics founded?

    Akari Therapeutics was founded in 2004.

  • Where is Akari Therapeutics headquartered?

    Akari Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Akari Therapeutics?

    Akari Therapeutics has 16 total employees.

  • What industry is Akari Therapeutics in?

    Akari Therapeutics’s primary industry is Drug Discovery.

  • Is Akari Therapeutics a private or public company?

    Akari Therapeutics is a Public company.

  • What is Akari Therapeutics’s stock symbol?

    The ticker symbol for Akari Therapeutics is AKTX.

  • What is the current stock price of Akari Therapeutics?

    As of 13-Nov-2026 the stock price of Akari Therapeutics is $6.80.

  • What is the current market cap of Akari Therapeutics?

    The current market capitalization of Akari Therapeutics is $15.5M.

  • Who are Akari Therapeutics’s competitors?

    Apellis Pharmaceuticals, EpimAb Biotherapeutics, BeOne Medicines, CytomX Therapeutics, and Cogent Biosciences are some of the 57 competitors of Akari Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process